Although the hypotensive effect of GLP-1 RAs seems to be manifested by BW losing, other mechanisms not related to BW might be implied by the mediation meta-analysis, which suggests an existence of BW-independent hypotensive effect of GLP-1 RA, along with the clinical evidence of weak or no correlations, and difference in time course between BP lowering and BW reducing effects
I have seen patients who are taking three glucose-lowering medications
It is available as a delayed-release capsule, pills, capsule, and solution
The difficult part for the consumer is there are no regulations on these research companies and unless you test every product by a 3rd party every time you get a product, you wont know the quality of the product
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg for 4 weeks (a non-therapeutic initiation dose to improve tolerability), then increased every 4 weeks to reach a therapeutic dose of 5-15 mg weekly based on response and tolerability